Prescription-grade crystalline glucosamine sulfate as an add-on therapy to conventional treatments in erosive osteoarthritis of the hand: results from a 6-month observational retrospective study.
Erosive hand osteoarthritis; Hand osteoarthritis; Pain; Prescription-grade crystalline glucosamine sulfate; Retrospective study; Symptomatic slow-acting drugs for osteoarthritis; Geriatrics and Gerontology; Aging
Abstract :
[en] OBJECTIVE: To evaluate the efficacy of prescription-grade Crystalline Glucosamine Sulfate (pCGS) as an add-on treatment to conventional therapy, compared to usual therapy alone, in patients with erosive osteoarthritis of the hand (EHOA).
METHODS: This 6-month retrospective case-control study included patients with concomitant knee osteoarthritis and symptomatic EHOA. Participants were stratified into two groups based on whether or not pCGS (1500 mg/day) was added to the conventional therapy (education and training in ergonomic principles, exercise and use on-demand of symptomatic drugs) for hand osteoarthritis. Patients were evaluated at baseline, after 3 and 6 months. Primary outcomes were the change from baseline to month 6 in Visual Analogue Scale (VAS) hand pain and in Functional Index for Hand Osteoarthritis (FIHOA) score. A set of secondary parameters was also evaluated.
RESULTS: 123 patients were included as follows: 67 treated with pCGS in addition to conventional therapy (pCGS Group) and 56 with conventional therapy alone (Control Group). After 6 months a significant difference in VAS and in FIHOA score (p < 0.01 and p < 0.001, respectively) was observed in favor of pCGS Group. Similar results were found for morning stiffness duration (p < 0.05), health assessment questionnaire (p < 0.01) and physical and mental component score of 36-item short form (p < 0.05 and p < 0.001, respectively). A significant reduction of symptomatic drug consumption at 3 and 6 months was reported in the pCGS Group (p < 0.001). No serious adverse event was recorded in both groups.
CONCLUSIONS: Despite all the limitations inherent to an observational study, our results suggest the potential effectiveness of pCGS, when used in combination with conventional therapy in EHOA. Further randomized placebo-controlled trials are needed to confirm these positive findings.
TRIAL REGISTRATION: ClinicalTrials.gov, http://www.
CLINICALTRIALS: gov , date of registration: February 2, 2022, NCT05237596. The present trial was retrospectively registered.
Disciplines :
Public health, health care sciences & services
Author, co-author :
Tenti, Sara; Clinic for the Diagnosis and Management of Hand Osteoarthritis, Rheumatology Unit, Department of Medicine, Surgery and Neuroscience, Azienda Ospedaliera Universitaria Senese, Policlinico Le Scotte, Viale Bracci 1, 53100, Siena, Italy
Veronese, Nicola; Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy
Cheleschi, Sara; Clinic for the Diagnosis and Management of Hand Osteoarthritis, Rheumatology Unit, Department of Medicine, Surgery and Neuroscience, Azienda Ospedaliera Universitaria Senese, Policlinico Le Scotte, Viale Bracci 1, 53100, Siena, Italy
Seccafico, Iole; Clinic for the Diagnosis and Management of Hand Osteoarthritis, Rheumatology Unit, Department of Medicine, Surgery and Neuroscience, Azienda Ospedaliera Universitaria Senese, Policlinico Le Scotte, Viale Bracci 1, 53100, Siena, Italy
BRUYERE, Olivier ; Université de Liège - ULiège > Unité de recherche Santé publique, épidémiologie et économie de la santé (URSAPES)
Reginster, Jean-Yves ; Université de Liège - ULiège > Unité de recherche Santé publique, épidémiologie et économie de la santé (URSAPES)
Fioravanti, Antonella ; Clinic for the Diagnosis and Management of Hand Osteoarthritis, Rheumatology Unit, Department of Medicine, Surgery and Neuroscience, Azienda Ospedaliera Universitaria Senese, Policlinico Le Scotte, Viale Bracci 1, 53100, Siena, Italy. fioravanti7@virgilio.it
Language :
English
Title :
Prescription-grade crystalline glucosamine sulfate as an add-on therapy to conventional treatments in erosive osteoarthritis of the hand: results from a 6-month observational retrospective study.
Qin J, Barbour KE, Murphy LB et al (2017) Lifetime Risk of Symptomatic Hand Osteoarthritis: The Johnston County Osteoarthritis Project. Arthritis Rheumatol 69:1204–1212. 10.1002/art.40097 DOI: 10.1002/art.40097
Arthritis Foundation (2019) Osteoarthritis of the Hands. https://www.arthritis.org/diseases/more-about/osteoarthritis-of-the-hands
Addimanda O, Mancarella L, Dolzani P et al (2012) Clinical and radiographic distribution of structural damage in erosive and nonerosive hand osteoarthritis. Arthritis Care Res (Hoboken) 64:1046–1053. 10.1002/acr.21658 DOI: 10.1002/acr.21658
Gazeley DJ, Yeturi S, Patel PJ et al (2017) Erosive osteoarthritis: A systematic analysis of definitions used in the literature. Semin Arthritis Rheum 46:395–403. 10.1016/j.semarthrit.2016.08.013 DOI: 10.1016/j.semarthrit.2016.08.013
Marshall M, Watt FE, Vincent TL et al (2018) Hand osteoarthritis: clinical phenotypes, molecular mechanisms and disease management. Nat Rev Rheumatol 14:641–656. 10.1038/s41584-018-0095-4 DOI: 10.1038/s41584-018-0095-4
Favero M, Belluzzi E, Ortolan A et al (2022) Erosive hand osteoarthritis: latest findings and outlook. Nat Rev Rheumatol. 10.1038/s41584-021-00747-3 DOI: 10.1038/s41584-021-00747-3
Marshall M, Nicholls E, Kwok WY et al (2015) Erosive osteoarthritis: a more severe form of radiographic hand osteoarthritis rather than a distinct entity? Ann Rheum Dis 74:136–141. 10.1136/annrheumdis-2013-203948 DOI: 10.1136/annrheumdis-2013-203948
Poletto E, Tinazzi I, Marchetta A et al (2021) Hand erosive osteoarthritis and distal interphalangeal involvement in psoriatic arthritis: the place of conservative therapy. J Clin Med 10:2630. 10.3390/jcm10122630 DOI: 10.3390/jcm10122630
Tenti S, Ferretti F, Gusinu R et al (2020) Impact of thumb osteoarthritis on pain, function, and quality of life: a comparative study between erosive and non-erosive hand osteoarthritis. Clin Rheumatol 39:2195–2206. 10.1007/s10067-020-04982-z DOI: 10.1007/s10067-020-04982-z
McAlindon TE, Driban JB, Roberts MB et al (2021) Erosive hand osteoarthritis: incidence and predictive characteristics among participants in the osteoarthritis initiative. Arthritis Rheumatol 73:2015–2024. 10.1002/art.41757 DOI: 10.1002/art.41757
Verbruggen G, Wittoek R, Vander Cruyssen B et al (2012) Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann Rheum Dis 71:891–898. 10.1136/ard.2011.149849 DOI: 10.1136/ard.2011.149849
Chevalier X, Ravaud P, Maheu E, et al.; French Section of Osteoarthritis (2015) Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis 74:1697–1705. https://doi.org/10.1136/annrheumdis-2014-205348
Aitken D, Laslett LL, Pan F et al (2018) A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial. Osteoarthr Cartil 26:880–887. 10.1016/j.joca.2018.02.899 DOI: 10.1016/j.joca.2018.02.899
Kingsbury SR, Tharmanathan P, Keding A et al (2018) Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: a randomized trial. Ann Intern Med 168:385–395. 10.7326/M17-1430 DOI: 10.7326/M17-1430
Kloppenburg M, Ramonda R, Bobacz K et al (2018) Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 77:1757–1764. 10.1136/annrheumdis-2018-213202 DOI: 10.1136/annrheumdis-2018-213202
Lee W, Ruijgrok L, Boxma-de Klerk B et al (2018) Efficacy of hydroxychloroquine in hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 70:1320–1325. 10.1002/acr.23471 DOI: 10.1002/acr.23471
Kloppenburg M, Peterfy C, Haugen IK et al (2019) Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Ann Rheum Dis 78:413–420. 10.1136/annrheumdis-2018-213336 DOI: 10.1136/annrheumdis-2018-213336
Richette P, Latourte A, Sellam J et al (2020) Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. Ann Rheum Dis. 10.1136/annrheumdis-2020-218547 DOI: 10.1136/annrheumdis-2020-218547
Ferrero S, Wittoek R, Allado E et al (2021) Methotrexate treatment in hand osteoarthritis refractory to usual treatments: a randomised, double-blind, placebo-controlled trial. Semin Arthritis Rheum 51:831–838. 10.1016/j.semarthrit.2021.04.016 DOI: 10.1016/j.semarthrit.2021.04.016
Kedor C, Detert J, Rau R et al (2021) Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. RMD Open 7:e001660. 10.1136/rmdopen-2021-001660 DOI: 10.1136/rmdopen-2021-001660
Kloppenburg M, Kroon FP, Blanco FJ et al (2019) 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis 78:16–24. 10.1136/annrheumdis-2018-213826 DOI: 10.1136/annrheumdis-2018-213826
Gabay C, Medinger-Sadowski C, Gascon D et al (2011) Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum 63:3383–3391. 10.1002/art.30574 DOI: 10.1002/art.30574
Rovetta G, Monteforte P, Molfetta G et al (2004) A two-year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction. Drugs Exp Clin Res 30:11–16
Largo R, Alvarez-Soria MA, Díez-Ortego I et al (2003) Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthr Cartil 11:290–298. 10.1016/s1063-4584(03)00028-1 DOI: 10.1016/s1063-4584(03)00028-1
Cheleschi S, Tenti S, Giannotti S et al (2021) A combination of celecoxib and glucosamine sulfate has anti-inflammatory and chondroprotective effects: results from an in vitro study on human osteoarthritic chondrocytes. Int J Mol Sci 22:8980. 10.3390/ijms22168980 DOI: 10.3390/ijms22168980
Reginster JY, Deroisy R, Rovati LC et al (2001) Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357:251–256. 10.1016/S0140-6736(00)03610-2 DOI: 10.1016/S0140-6736(00)03610-2
Pavelka K, Bruyere O, Rovati LC et al (2003) Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials. Osteoarthr Cartil 11:730–737. 10.1016/s1063-4584(03)00166-3 DOI: 10.1016/s1063-4584(03)00166-3
Towheed TE, Maxwell L, Anastassiades TP et al (2005) Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 10.1002/14651858.CD002946.pub2 DOI: 10.1002/14651858.CD002946.pub2
Herrero-Beaumont G, Ivorra JA, Del Carmen TM et al (2007) Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 56:555–567. 10.1002/art.22371 DOI: 10.1002/art.22371
Giordano N, Fioravanti A, Papakostas P et al (2009) The efficacy and tolerability of glucosamine sulfate in the treatment of knee osteoarthritis: A randomized, double-blind, placebo-controlled trial. Curr Ther Res Clin Exp 70:185–196. 10.1016/j.curtheres.2009.05.004 DOI: 10.1016/j.curtheres.2009.05.004
Bruyère O, Reginster JY, Honvo G et al (2019) Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies. Aging Clin Exp Res 31:881–887. 10.1007/s40520-019-01138-1 DOI: 10.1007/s40520-019-01138-1
Bruyère O, Cooper C, Pelletier JP et al (2014) An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 44:253–263. 10.1016/j.semarthrit.2014.05.014 DOI: 10.1016/j.semarthrit.2014.05.014
Bruyère O, Cooper C, Pelletier JP et al (2016) A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum 45:S3-11. 10.1016/j.semarthrit.2015.11.010 DOI: 10.1016/j.semarthrit.2015.11.010
Bruyère O, Honvo G, Veronese N et al (2019) An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum 49:337–350. 10.1016/j.semarthrit.2019.04.008 DOI: 10.1016/j.semarthrit.2019.04.008
Tenti S, Giordano N, Mondanelli N et al (2020) A retrospective observational study of glucosamine sulfate in addition to conventional therapy in hand osteoarthritis patients compared to conventional treatment alone. Aging Clin Exp Res 32:1161–1172. 10.1007/s40520-019-01305-4 DOI: 10.1007/s40520-019-01305-4
Agenzia Italiana del Farmaco (AIFA). Guideline for the classification and conduction of the observational studies on medicines. http://www.agenziafarmaco.gov.it/allegati/det_20marzo2008.pdf. Accessed 30 Mar 2022
Altman R, Asch E, Bloch D et al (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 29:1039–1049. 10.1002/art.1780290816 DOI: 10.1002/art.1780290816
Fioravanti A, Cheleschi S, De Palma A et al (2018) Can adipokines serum levels be used as biomarkers of hand osteoarthritis? Biomarkers 23:265–270. 10.1080/1354750X.2017.1401665 DOI: 10.1080/1354750X.2017.1401665
Kellgren JH, Lawrence JS (1957) Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16:494–502. 10.1136/ard.16.4.494 DOI: 10.1136/ard.16.4.494
Østerås N, Hagen KB, Grotle M et al (2014) Exercise programme with telephone follow-up for people with hand osteoarthritis - protocol for a randomised controlled trial. BMC Musculoskelet Disord 15:82. 10.1186/1471-2474-15-82 DOI: 10.1186/1471-2474-15-82
Østerås N, Kjeken I, Smedslund G et al (2017) Exercise for hand osteoarthritis: a cochrane systematic review. J Rheumatol 44:1850–1858. 10.3899/jrheum.170424 DOI: 10.3899/jrheum.170424
Ariani A, Manara M, Fioravanti A et al (2019) The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of knee, hip and hand osteoarthritis. Reumatismo 71:5–21. 10.4081/reumatismo.2019.1188 DOI: 10.4081/reumatismo.2019.1188
Dreiser RL, Maheu E, Guillou GB (2000) Sensitivity to change of the functional index for hand osteoarthritis. Osteoarthr Cartil 8:S25–S28. 10.1053/joca.2000.0332 DOI: 10.1053/joca.2000.0332
Gandini F, Giannitti C, Fattore G et al (2012) Validation of an Italian version of the functional index for hand osteoarthritis (FIHOA). Mod Rheumatol 22:758–765. 10.1007/s10165-011-0579-4 DOI: 10.1007/s10165-011-0579-4
Ranza R, Marchesoni A, Calori G et al (1993) The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 11:123–128
Bruce B, Fries JF (2003) The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 1:20. 10.1186/1477-7525-1-20 DOI: 10.1186/1477-7525-1-20
Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483 DOI: 10.1097/00005650-199206000-00002
Apolone G, Mosconi P (1998) The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 51:1025–1036. 10.1016/s0895-4356(98)00094-8 DOI: 10.1016/s0895-4356(98)00094-8
Pham T, van der Heijde D, Altman RD et al (2004) OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthr Cartil 12:389–399. 10.1016/j.joca.2004.02.001 DOI: 10.1016/j.joca.2004.02.001
Bijsterbosch J, Watt I, Meulenbelt I et al (2010) Clinical burden of erosive hand osteoarthritis and its relationship to nodes. Ann Rheum Dis 69:1784–1788. 10.1136/ard.2009.125435 DOI: 10.1136/ard.2009.125435
Michon M, Maheu E, Berenbaum F (2011) Assessing health-related quality of life in hand osteoarthritis: a literature review. Ann Rheum Dis 70:921–928. 10.1136/ard.2010.131151 DOI: 10.1136/ard.2010.131151
Bruyere O, Pavelka K, Rovati LC et al (2008) Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthr Cartil 16:254–260. 10.1016/j.joca.2007.06.011 DOI: 10.1016/j.joca.2007.06.011
Rovati LC, Girolami F, D’Amato M et al (2016) Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: Results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum 45:S34-41. 10.1016/j.semarthrit.2015.10.009 DOI: 10.1016/j.semarthrit.2015.10.009
Fioravanti A, Fabbroni M, Cerase A et al (2009) Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int 29:961–965. 10.1007/s00296-009-0872-0 DOI: 10.1007/s00296-009-0872-0
Fioravanti A, Tenti S, McAllister M et al (2019) Exploring the Involvement of NLRP3 and IL-1β in Osteoarthritis of the Hand: Results from a Pilot Study. Mediators Inflamm 2019:2363460. 10.1155/2019/2363460 DOI: 10.1155/2019/2363460
Davis CR, Ruediger CD, Dyer KA et al (2021) Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH). Osteoarthr Cartil 29:208–214. 10.1016/j.joca.2020.11.002 DOI: 10.1016/j.joca.2020.11.002
Saviola G, Abdi-Ali L, Campostrini L et al (2012) Clodronate and hydroxychloroquine in erosive osteoarthritis: a 24-month open randomized pilot study. Mod Rheumatol 22:256–263. 10.1007/s10165-011-0506-8 DOI: 10.1007/s10165-011-0506-8
Saviola G, Abdi-Ali L, Povino MR et al (2017) Intramuscular clodronate in erosive osteoarthritis of the hand is effective on pain and reduces serum COMP: a randomized pilot trial-The ER.O.D.E. study (ERosive Osteoarthritis and Disodium-clodronate Evaluation). Clin Rheumatol 36:2343–2350. 10.1007/s10067-017-3681-y DOI: 10.1007/s10067-017-3681-y
Felson DT, Neogi T (2018) Emerging treatment models in rheumatology: challenges for osteoarthritis trials. Arthritis Rheumatol 70:1175–1181. 10.1002/art.40515 DOI: 10.1002/art.40515
Kucharz EJ, Kovalenko V, Szántó S et al (2016) A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin 32:997–1004. 10.1185/03007995.2016.1154521 DOI: 10.1185/03007995.2016.1154521
Bruyère O, Cooper C, Al-Daghri NM et al (2018) Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res 30:111–117. 10.1007/s40520-017-0861-1 DOI: 10.1007/s40520-017-0861-1
Reginster JL, Bruyere O, Cooper C (2018) Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms. Ann Rheum Dis 77:e39. 10.1136/annrheumdis-2017-212251 DOI: 10.1136/annrheumdis-2017-212251
Veronese N, Demurtas J, Smith L, et al.; on behalf on the European Geriatric Medicine Society Special Interest Groups in Systematic Reviews and Meta-Analyses and Arthritis (2020) Glucosamine sulphate: an umbrella review of health outcomes. Ther Adv Musculoskelet Dis 12:1759720X20975927. 10.1177/1759720X20975927
Persiani S, Roda E, Rovati LC et al (2005) Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthr Cartil 13:1041–1049. 10.1016/j.joca.2005.07.009 DOI: 10.1016/j.joca.2005.07.009
Persiani S, Rotini R, Trisolino G et al (2007) Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthr Cartil 15:764–772. 10.1016/j.joca.2007.01.019 DOI: 10.1016/j.joca.2007.01.019
Chiusaroli R, Piepoli T, Zanelli T et al (2011) Experimental pharmacology of glucosamine sulfate. Int J Rheumatol 2011:939265. 10.1155/2011/939265 DOI: 10.1155/2011/939265
Bruyère O, Altman RD, Reginster JY (2016) Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum 45:S12-17. 10.1016/j.semarthrit.2015.11.011 DOI: 10.1016/j.semarthrit.2015.11.011
Gregori D, Giacovelli G, Minto C et al (2018) Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA 320:2564–2579. 10.1001/jama.2018.19319 DOI: 10.1001/jama.2018.19319
Beaudart C, Lengelé L, Leclercq V et al (2020) Symptomatic efficacy of pharmacological treatments for knee osteoarthritis: a systematic review and a network meta-analysis with a 6-month time horizon. Drugs 80:1947–1959. 10.1007/s40265-020-01423-8 DOI: 10.1007/s40265-020-01423-8
Zou K, Wong J, Abdullah N et al (2016) Examination of overall treatment effect and the proportion attributable to contextual effect in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 75:1964–1970. 10.1136/annrheumdis-2015-208387 DOI: 10.1136/annrheumdis-2015-208387
Nakagawa Y, Tatebe M, Yamamoto M et al (2021) Choice of control group treatments in hand osteoarthritis trials: a systematic review and meta-analysis. Semin Arthritis Rheum 51:775–785. 10.1016/j.semarthrit.2021.04.006 DOI: 10.1016/j.semarthrit.2021.04.006
Kloppenburg M, Maheu E, Kraus VB, et al.; OARSI Hand Clinical Trial Recommendations Work Group (2015) OARSI Clinical Trials Recommendations: design and conduct of clinical trials for hand osteoarthritis. Osteoarthr Cartil 23:772–786. 10.1016/j.joca.2015.03.007
Reginster JL, Arden NK, Haugen IK et al (2018) Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum 48:1–8. 10.1016/j.semarthrit.2017.12.003 DOI: 10.1016/j.semarthrit.2017.12.003
Kroon FPB, van der Heijde D, Maxwell LJ et al (2021) Core outcome measurement instrument selection for physical function in hand osteoarthritis using the OMERACT Filter 2.1 process. Semin Arthritis Rheum 51:1311–1319. 10.1016/j.semarthrit.2021.08.014 DOI: 10.1016/j.semarthrit.2021.08.014
